DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets

To identify the physiological targets of drugs and bioactive small molecules we have developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and CRISPR/Cas9-based genome editing. We apply this approach to ispinesib and YM155, drugs tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasap, Corynn, Elemento, Olivier, Kapoor, Tarun M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123312/
https://www.ncbi.nlm.nih.gov/pubmed/24929528
http://dx.doi.org/10.1038/nchembio.1551
_version_ 1782329492382941184
author Kasap, Corynn
Elemento, Olivier
Kapoor, Tarun M.
author_facet Kasap, Corynn
Elemento, Olivier
Kapoor, Tarun M.
author_sort Kasap, Corynn
collection PubMed
description To identify the physiological targets of drugs and bioactive small molecules we have developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and CRISPR/Cas9-based genome editing. We apply this approach to ispinesib and YM155, drugs that have undergone clinical trials as anti-cancer agents, and demonstrate target identification and uncover genetic and epigenetic mechanisms likely to cause drug resistance in human cancer cells.
format Online
Article
Text
id pubmed-4123312
institution National Center for Biotechnology Information
language English
publishDate 2014
record_format MEDLINE/PubMed
spelling pubmed-41233122015-02-01 DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets Kasap, Corynn Elemento, Olivier Kapoor, Tarun M. Nat Chem Biol Article To identify the physiological targets of drugs and bioactive small molecules we have developed an approach, named DrugTargetSeqR, which combines high-throughput sequencing, computational mutation discovery and CRISPR/Cas9-based genome editing. We apply this approach to ispinesib and YM155, drugs that have undergone clinical trials as anti-cancer agents, and demonstrate target identification and uncover genetic and epigenetic mechanisms likely to cause drug resistance in human cancer cells. 2014-06-15 2014-08 /pmc/articles/PMC4123312/ /pubmed/24929528 http://dx.doi.org/10.1038/nchembio.1551 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Kasap, Corynn
Elemento, Olivier
Kapoor, Tarun M.
DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title_full DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title_fullStr DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title_full_unstemmed DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title_short DrugTargetSeqR: a genomics- and CRISPR/Cas9-based method to analyze drug targets
title_sort drugtargetseqr: a genomics- and crispr/cas9-based method to analyze drug targets
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123312/
https://www.ncbi.nlm.nih.gov/pubmed/24929528
http://dx.doi.org/10.1038/nchembio.1551
work_keys_str_mv AT kasapcorynn drugtargetseqragenomicsandcrisprcas9basedmethodtoanalyzedrugtargets
AT elementoolivier drugtargetseqragenomicsandcrisprcas9basedmethodtoanalyzedrugtargets
AT kapoortarunm drugtargetseqragenomicsandcrisprcas9basedmethodtoanalyzedrugtargets

Ejemplares similares